We are live on !
Find out more
CCM
Cupps Capital Management Portfolio holdings
AUM
$231M
Turnover
35.92%
1-Year Est. Return
49.73%
This Fund
S&P 500
This Quarter Est. Return
+19.18%
1 Year Est. Return
+49.73%
3 Year Est. Return
+212.7%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$231M
AUM Growth
-$156M
(-40%)
Cap. Flow
-$194M
Cap. Flow % of AUM
Cap. Flow %
-83.99%
Top 10 Holdings %
Top 10 Hldgs %
24.21%
Holding
206
New
45
Increased
20
Reduced
112
Closed
29
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDSO
Medidata Solutions, Inc.
MDSO
|
+$2.5M |
| 2 |
Glaukos
GKOS
|
+$2.17M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
+$1.61M |
| 4 |
CAVM
Cavium, Inc.
CAVM
|
+$1.52M |
| 5 |
bluebird bio
BLUE
|
+$1.51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$9.12M |
| 2 |
NEVRO CORP.
NVRO
|
+$8.36M |
| 3 |
Amazon
AMZN
|
+$7.51M |
| 4 |
Burlington
BURL
|
+$6.63M |
| 5 |
Texas Roadhouse
TXRH
|
+$5.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.04% |
| 2 | Healthcare | 24.89% |
| 3 | Consumer Discretionary | 10.15% |
| 4 | Industrials | 9.46% |
| 5 | Real Estate | 3.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
NEVRO CORP.
NVRO
| $9.06M | 3.92% |
86,799
-92,571
| -52% | -$8.36M |
2015 Q1
6 quarters
|
|
|
ABMD
2
DELISTED
Abiomed Inc
ABMD
| $7.78M | 3.37% |
60,492
-76,161
| -56% | -$9.12M |
2014 Q3
8 quarters
|
|
|
ZEN
3
DELISTED
ZENDESK INC
ZEN
| $6.12M | 2.65% |
199,196
-9,557
| -5% | -$284K |
2015 Q4
3 quarters
|
|
4
Paycom
PAYC
$11.3B
| $6M | 2.6% |
119,720
-63,505
| -35% | -$3.1M |
2015 Q2
5 quarters
|
|
5
Tyler Technologies
TYL
$14.6B
| $5.85M | 2.53% |
34,160
-25,359
| -43% | -$4.23M |
2015 Q3
4 quarters
|
|
|
PFPT
6
DELISTED
Proofpoint, Inc.
PFPT
| $5.12M | 2.22% |
68,466
-18,934
| -22% | -$1.4M |
2015 Q4
3 quarters
|
|
7
DELISTED
Ultimate Software Group Inc
ULTI
| $4.12M | 1.78% |
20,162
-15,107
| -43% | -$3.19M |
2013 Q2
13 quarters
|
|
8
DELISTED
2U Inc
TWOU
| $4.02M | 1.74% |
3,504
+435
| +14% | +$454K |
2016 Q2
1 quarter
|
|
|
9
Burlington
BURL
$16.6B
| $3.93M | 1.7% |
48,502
-85,690
| -64% | -$6.63M |
2016 Q1
2 quarters
|
|
10
Vail Resorts
MTN
$5.41B
| $3.92M | 1.7% |
24,982
-16,472
| -40% | -$2.51M |
2014 Q3
8 quarters
|
|
|
NEWR
11
DELISTED
New Relic, Inc.
NEWR
| $3.8M | 1.64% |
99,180
-47,354
| -32% | -$1.66M |
2015 Q3
4 quarters
|
|
|
ELLI
12
DELISTED
Ellie Mae Inc
ELLI
| $3.7M | 1.6% |
35,092
+592
| +2% | +$57.4K |
2016 Q1
2 quarters
|
|
13
DELISTED
Berry Global Group, Inc.
BERY
| $3.58M | 1.55% |
88,785
-38,949
| -30% | -$1.53M |
2014 Q2
9 quarters
|
|
14
HubSpot
HUBS
$11.4B
| $3.51M | 1.52% |
60,930
-15,410
| -20% | -$836K |
2015 Q3
4 quarters
|
|
|
CAVM
15
DELISTED
Cavium, Inc.
CAVM
| $3.31M | 1.43% |
56,822
+30,356
| +115% | +$1.52M |
2014 Q2
9 quarters
|
|
16
MACOM Technology Solutions
MTSI
$20.7B
| $3.2M | 1.39% |
75,645
-14,320
| -16% | -$561K |
2015 Q4
3 quarters
|
|
17
Edwards Lifesciences
EW
$50.1B
| $2.8M | 1.21% |
69,681
-121,311
| -64% | -$4.57M |
2014 Q3
8 quarters
|
|
18
DexCom
DXCM
$32.5B
| $2.69M | 1.16% |
122,736
-156,288
| -56% | -$3.48M |
2013 Q2
13 quarters
|
|
|
MDSO
19
DELISTED
Medidata Solutions, Inc.
MDSO
| $2.63M | 1.14% |
+47,254
| New | +$2.5M |
2016 Q3
0 quarters
|
|
20
Applied Materials
AMAT
$337B
| $2.62M | 1.13% |
86,871
-99,980
| -54% | -$2.79M |
2016 Q1
2 quarters
|
|
|
21
Glaukos
GKOS
$9.7B
| $2.48M | 1.07% |
+65,680
| New | +$2.17M |
2016 Q3
0 quarters
|
|
22
DELISTED
Electronic Arts
EA
| $2.43M | 1.05% |
28,413
-14,229
| -33% | -$1.14M |
2014 Q2
9 quarters
|
|
23
XPO
XPO
$21.8B
| $2.35M | 1.02% |
185,656
+79,120
| +74% | +$895K |
2015 Q1
6 quarters
|
|
24
Nektar Therapeutics
NKTR
$1.22B
| $2.33M | 1.01% |
9,027
-2,143
| -19% | -$552K |
2015 Q4
3 quarters
|
|
|
NXTM
25
DELISTED
NxStage Medical Inc.
NXTM
| $2.29M | 0.99% |
91,711
-5,024
| -5% | -$117K |
2016 Q2
1 quarter
|
|
Similar funds
SA
WIM
EDRE
RIG
VBCP
TI
ZBI
MI
Cupps Capital Management's Q3 2016 Portfolio in Review
As of Q3 2016, Cupps Capital Management held 206 positions worth $231M, down 40% from $387M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Cupps Capital Management withdrew a net $194M in Q3 2016, closing 29 positions and reducing 112 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $3.68M position sold in full.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Cupps Capital Management opened a new position in Medidata Solutions, Inc. worth $2.63M.
- Cupps Capital Management's largest Q3 2016 buy was Medidata Solutions, Inc.: 47,254 shares worth $2.63M.
- Cupps Capital Management added most to Cavium, Inc. in Q3 2016, an estimated $1.52M increase.
- Cupps Capital Management's biggest Q3 2016 reduction was Abiomed Inc, cutting an estimated $9.12M.
- Cupps Capital Management fully exited Bristol-Myers Squibb in Q3 2016, selling an estimated $3.68M.
- Cupps Capital Management's ten largest holdings make up 24% of its $231M portfolio in Q3 2016.
- Cupps Capital Management opened 45 new positions and closed 29 in Q3 2016.
- Cupps Capital Management's portfolio value fell 40% quarter-over-quarter to $231M.
Based on Cupps Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.